The relative contributions of infectious and mitotic spread to HTLV-1 persistence.
Journal
PLoS computational biology
ISSN: 1553-7358
Titre abrégé: PLoS Comput Biol
Pays: United States
ID NLM: 101238922
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
04
10
2019
accepted:
31
07
2020
revised:
29
09
2020
pubmed:
18
9
2020
medline:
21
10
2020
entrez:
17
9
2020
Statut:
epublish
Résumé
Human T-lymphotropic virus type-1 (HTLV-1) persists within hosts via infectious spread (de novo infection) and mitotic spread (infected cell proliferation), creating a population structure of multiple clones (infected cell populations with identical genomic proviral integration sites). The relative contributions of infectious and mitotic spread to HTLV-1 persistence are unknown, and will determine the efficacy of different approaches to treatment. The prevailing view is that infectious spread is negligible in HTLV-1 persistence beyond early infection. However, in light of recent high-throughput data on the abundance of HTLV-1 clones, and recent estimates of HTLV-1 clonal diversity that are substantially higher than previously thought (typically between 104 and 105 HTLV-1+ T cell clones in the body of an asymptomatic carrier or patient with HTLV-1-associated myelopathy/tropical spastic paraparesis), ongoing infectious spread during chronic infection remains possible. We estimate the ratio of infectious to mitotic spread using a hybrid model of deterministic and stochastic processes, fitted to previously published HTLV-1 clonal diversity estimates. We investigate the robustness of our estimates using three alternative estimators. We find that, contrary to previous belief, infectious spread persists during chronic infection, even after HTLV-1 proviral load has reached its set point, and we estimate that between 100 and 200 new HTLV-1 clones are created and killed every day. We find broad agreement between all estimators. The risk of HTLV-1-associated malignancy and inflammatory disease is strongly correlated with proviral load, which in turn is correlated with the number of HTLV-1-infected clones, which are created by de novo infection. Our results therefore imply that suppression of de novo infection may reduce the risk of malignant transformation.
Identifiants
pubmed: 32941445
doi: 10.1371/journal.pcbi.1007470
pii: PCOMPBIOL-D-19-01729
pmc: PMC7524007
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1007470Subventions
Organisme : Wellcome Trust
ID : 103865
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/J007439/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 207477/Z/17/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 100291
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1001052
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R015600/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 091845
Pays : United Kingdom
Organisme : Medical Research Council
ID : J007439
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet Oncol. 2014 Oct;15(11):e517-26
pubmed: 25281470
Blood. 2014 Jun 19;123(25):3925-31
pubmed: 24735963
Blood. 1996 Dec 15;88(12):4646-50
pubmed: 8977257
Front Microbiol. 2012 Nov 15;3:388
pubmed: 23162541
J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S92-9
pubmed: 8797710
J Virol. 1995 May;69(5):2863-8
pubmed: 7707509
Int J Cancer. 2004 Jul 1;110(4):621-5
pubmed: 15122598
Oncogene. 2000 Oct 12;19(43):4954-60
pubmed: 11042682
Blood. 2011 Mar 17;117(11):3113-22
pubmed: 21228324
AIDS Res Hum Retroviruses. 2013 Feb;29(2):359-64
pubmed: 22894552
Science. 2001 May 11;292(5519):1106-9
pubmed: 11352065
Elife. 2020 Mar 18;9:
pubmed: 32187010
Curr Opin Neurobiol. 1993 Oct;3(5):773-8
pubmed: 8260828
Bull Math Biol. 2008 Nov;70(8):2283-302
pubmed: 18716844
J Infect Dis. 2005 Apr 1;191(7):1140-7
pubmed: 15747250
Sci Rep. 2017 Dec 1;7(1):16788
pubmed: 29196717
PLoS Pathog. 2013;9(4):e1003263
pubmed: 23592987
Bioinformatics. 2012 Mar 15;28(6):755-62
pubmed: 22238265
Philos Trans R Soc Lond B Biol Sci. 2015 Aug 19;370(1675):
pubmed: 26150657
PLoS Pathog. 2008 Mar 21;4(3):e1000027
pubmed: 18369476
Blood. 1992 Aug 15;80(4):1012-6
pubmed: 1498321
PLoS Comput Biol. 2014 Jun 19;10(6):e1003646
pubmed: 24945836
J Virol. 1999 Dec;73(12):10289-95
pubmed: 10559346
Virol J. 2014 Sep 30;11:172
pubmed: 25270762
J Neurovirol. 2001 Jun;7(3):228-34
pubmed: 11517397
Immunol Today. 1999 May;20(5):220-7
pubmed: 10322301
J Neurovirol. 1998 Dec;4(6):586-93
pubmed: 10065900
Nat Rev Dis Primers. 2015 Jun 18;1:15012
pubmed: 27188208
Proc Natl Acad Sci U S A. 2007 May 8;104(19):8035-40
pubmed: 17483473
J Clin Invest. 2010 Jun;120(6):1885-94
pubmed: 20440073